18 publications
Name | Date | Type | Actions |
---|---|---|---|
2023 HALF-YEAR RESULTS Sales: €256m (-5.4% as reported) |
Public releases | ||
2022 ANNUAL RESULTS Annual sales: €540m (up 3.6% as reported) |
Public releases | ||
First half 2019 results At its meeting on July 24, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited first half 2019 financial statements. |
Public releases | ||
2015 results sales of reference products up 9.4% ebit up 10.3% At its meeting on March 18, 2016, the Vetoquinol S.A. Board of Directors reviewed the Group’s results and approved the 2015 financial statements. |
Public releases | ||
Growth in all financial indicators in 2018. Essentials products sales: €179.4M (up 9.1% at constant exchange rates). Net income group share €36.3M (up 4.0%) At its meeting on March 19, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited 2018 financial statements. |
Public releases | ||
All key financial indicators up in 2016 At its meeting on March 22, 2017, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the 2016 financial statements. |
Public releases | ||
Reference products up 6.1% like-for-like in H1 net income group share up 6.5% to €14.4 million At its meeting on July 26, 2017, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the financial statements for the first half of 2017. |
Public releases | ||
Q1 sales: €85.8M Vetoquinol posted Q1 2016 sales of €85.8 million, representing organic growth of 7.7%. Changes in exchange rates resulted in a negative currency impact of 2.1%; reported sales for the first three months of 2016 grew by 5.6%. |
Public releases | ||
Vetoquinol finalizes acquisition of Clarion Biociencias in Brazil Lure (France), April 16, 2019 - Vetoquinol today confirms the completion of its acquisition of Clarion Biociências, a Brazilian veterinary laboratory based in the state of Goiás.
|
Public releases | ||
2018 sales: up 3.2% to €367.9 million 9.1% GROWTH IN ESSENTIALS PRODUCTS AT CONSTANT EXCHANGE RATES
|
Public releases |